Sarepta Therapeutics, Inc (SRPT)

Etorro trading 970x250
Sarepta Therapeutics, Inc (SRPT) Logo

About Sarepta Therapeutics, Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children’s Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. Address: 215 First Street, Cambridge, MA, United States, 02142

Sarepta Therapeutics, Inc News and around…

Latest news about Sarepta Therapeutics, Inc (SRPT) common stock and company :

Dyne Therapeutics (DYN) Submits IND to FDA for DMD Candidate
03 Dec, 2021 Yahoo! Finance

Dyne Therapeutics (DYN) files an investigational new drug application in the United States for a clinical study on its investigational candidate DYNE-251 to address Duchenne Muscular Dystrophy.

Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry
03 Dec, 2021 Yahoo! Finance

Blueprint Medicines' (BPMC) Ayvakit, which has been approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. However, stiff competition remains a headwind.

Why Is Sarepta Therapeutics (SRPT) Down 4.4% Since Last Earnings Report?
03 Dec, 2021 Yahoo! Finance

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Glaxo (GSK), Vir COVID Drug Appears Effective Against Omicron
03 Dec, 2021 Yahoo! Finance

Glaxo (GSK) and Vir Biotechnology announce promising pre-clinical data from the study of their antibody candidate, sotrovimab, against mutations found in the Omicron variant.

SRPT January 2022 Options Begin Trading
02 Dec, 2021 FinancialContent

Investors in Sarepta Therapeutics Inc (SRPT) saw new options begin trading today, for the January 2022 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SRPT options chain for the new January 2022 contracts and identified one put and one call contract of particular interest.

Vertex (VRTX) Up on Kidney Disease Drug's Success in Phase II
02 Dec, 2021 Yahoo! Finance

Vertex's (VRTX) APOL1 inhibitor, VX-147, led to a significant reduction in protein in urine in a phase II study in APOL1-mediated FSGS, a severe kidney disorder.

Merck (MRK) Vaxneuvance sBLA for Pediatrics Gets Priority Review
02 Dec, 2021 Yahoo! Finance

Merck (MRK) is seeking label expansion for Vaxneuvance for use in pediatric patients aged six weeks through 17 years for the prevention of invasive pneumococcal disease. A decision is expected by on Apr 1, 2022.

Fennec (FENC) Gets CRL From FDA for Pedmark, Stock Down
30 Nov, 2021 Yahoo! Finance

Fennec (FENC) suffers a setback again with a CRL for its new drug application (NDA) for Pedmark. Shares are down in pre-market trading.

Merck's (MRK) Keytruda Gets Europe Nod for Two Carcinomas
30 Nov, 2021 Yahoo! Finance

Merck's (MRK) Keytruda, in combination with Eisai's Lenvima, gets approval for treating first-line renal cell carcinoma and recurrent endometrial carcinoma in Europe.

Moore Kuehn, PLLC Encourages Investors of Sarepta Therapeutics, Inc. to Contact Law Firm
30 Nov, 2021 Yahoo! Finance

New York, New York--(Newsfile Corp. - November 30, 2021) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.If you own SRPT please contact Justin Kuehn, Esq. by email at or telephone at (2

Wall Street Analysts See a 60% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?
29 Nov, 2021 Yahoo! Finance

The mean of analysts' price targets for Sarepta Therapeutics (SRPT) points to a 59.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

These 60 stocks, including DraftKings, Zillow and Virgin Galactic, are down at least 50% from their 2021 highs
29 Nov, 2021 FinancialContent

Even a good year for stocks has its share of high-flyers that have turned into losers — or buying opportunities.

4 Reasons Why You Should Add Sarepta (SRPT) to Your Portfolio
26 Nov, 2021 Yahoo! Finance

Sarepta's (SRPT) stock creates a significant opportunity for investors on the back of solid demand for its commercialized drugs and steady progress with its key pipeline candidates.

Gilead Sciences (GILD) Stock Gains 20% YTD: What Lies Ahead?
26 Nov, 2021 Yahoo! Finance

Gilead's (GILD) performance in the year has been pretty good on contribution from Veklury. The company is now focusing on its oncology business as the virology business faces challenges.

Selecta (SELB) Down on FDA's Clinical Hold on Phase I/II Study
25 Nov, 2021 Yahoo! Finance

The FDA issues a clinical hold on Selecta's (SELB) phase I/II study evaluating SEL-302 for the treatment of patients with methylmalonic acidemia. Shares down in after-hours trading.

REGENXBIO (RGNX) DMD Gene Therapy Gets Orphan Drug Status
23 Nov, 2021 Yahoo! Finance

REGENXBIO (RGNX) is developing a gene therapy candidate, RGX-202, for treating DMD, which is currently in the pre-clinical stage. An IND application is expected by the end of 2021.

Strong Insider Buying Puts These 3 Stocks in Focus
23 Nov, 2021 Yahoo! Finance

Investors are always looking for the right signal, something that will indicate where a stock is likely to move. These can be positive or negative – what matters most is accuracy. The stock market is an expression of the collective will and opinions of millions of traders, investors, and corporate execs. The most successful stock players are those who learn to read what the signals are saying. One of the clearest signals comes from the corporate insiders. These company officers get an inside vie

BioMarin's (BMRN) Dwarfism Drug Gets FDA's Nod, Stock Up
22 Nov, 2021 Yahoo! Finance

Biomarin Pharmaceuticals's (BMRN) Voxzogo is the first medicine in the United States to be approved to treat achondroplasia, the most common form of dwarfism.

Thursday 11/18 Insider Buying Report: SRPT, DKNG
18 Nov, 2021 FinancialContent

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.

CEO Of Sarepta Therapeutics Makes $2.0M Buy
18 Nov, 2021 Yahoo! Finance

Douglas S Ingram, CEO at Sarepta Therapeutics (NASDAQ:SRPT), made a large insider buy on November 17, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Ingram purchased 25,026 shares of Sarepta Therapeutics at at a price of $79.94. The total transaction amounted to $2,000,578. Following the transaction, Ingram now owns 365,082 shares of the company, worth $30,024,343.00. Sarepta Therapeutics shares are trading

Biogen's (BIIB) Oral MS Drug Vumerity Gets Approval in Europe
17 Nov, 2021 Yahoo! Finance

Biogen's (BIIB) Vumerity gets marketing authorization in Europe for the treatment of adults with relapsing-remitting multiple sclerosis.

Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development
17 Nov, 2021 Yahoo! Finance

Gilmore O’Neill, M.B., M.M.Sc., will depart the Company and serve in a consulting capacity through March 31, 2022 CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that, effective immediately, Louise Rodino-Klapac, Ph.D., executive vice president and chief scientific officer, has been named the Company’s head of research and development (R&D) and will continue to serve in the r

Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021
05 Nov, 2021 FinancialContent

Upgrades For IGM Biosciences Inc (NASDAQ:IGMS), Wedbush upgraded the previous rating of Neutral to Outperform. IGM ...

Why Sarepta Therapeutics Shares Dropped More Than 16% This Week
04 Nov, 2021 FinancialContent

The biotech stock fell a little more than $72 since its close last Friday.

Analyst Ratings For Sarepta Therapeutics
04 Nov, 2021 FinancialContent

Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter: ...

Sarepta Therapeutics Larger Than S&P 500 Component HanesBrands
04 Nov, 2021 FinancialContent

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Sarepta Therapeutics Inc (SRPT) was identified as having a larger market cap than the smaller end of the S&P 500, for example HanesBrands Inc (HBI), according to The Online Investor. Click here to find out the top S&P 500 components ordered by average analyst rating » Market capitalization is an important data point for investors to keep an eye on, for various reasons..

Sarepta Therapeutics (SRPT) Q3 2021 Earnings Call Transcript
04 Nov, 2021 FinancialContent

SRPT earnings call for the period ending September 30, 2021.

The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
03 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement ...

Earnings Scheduled For November 3, 2021
03 Nov, 2021 FinancialContent

Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at ...

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
31 Oct, 2021 FinancialContent

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly ...

Sarepta Therapeutics, Inc (SRPT) is a NASDAQ Common Stock listed in , ,